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Prevalence of clear cell renal cell carcinoma (ccRCC) among human population though common among adults, it occurs 
in children and young adults as well. The prognostic value of P53 expression in ccRCC is well known. Recently, PBRM1 
has also acquired attention for its prognostic and predictive value in ccRCC. Here, we investigated the expression and 
correlation of PBRM1 and P53 in ccRCC. Renal tissues were collected from 70 patients who have undergone radical 
nephrectomy for clear cell carcinoma of the kidney in our hospital and 24 healthy volunteers for the study. We used 
immunohistochemical approach to determine the expression of PBRM1 and P53 in clear cell carcinoma of the kidney and 
normal kidney tissues and to analyze the correlation between them. Clinicopathological parameters and prognosis of patients 
were also studied. The positive expression rate of PBRM1 in clear renal cell carcinoma tissues was significantly higher 
(62.86%) compared to the normal renal tissues 8.33%. Similarly, positive expression rate of P53 in clear renal cell 
carcinoma tissues was 40%, while it was no expression in normal renal tissues. The expression level of PBRM1 was 
correlated with pathological grade and clinical stage of ccRCC patients, but not with age, sex and tumor size. P53 and 
expression levels were independent of age, sex, tumor size, pathological grade, and clinical stage of patients with clear cell 
carcinoma of the kidney. The 5-year survival rate of PBRM1 positive expression patients was 40.91% significantly lower 
than that of PBRM1 negative expression patients (84.62%), whereas in P53 it was 50 and 61.90%, respectively. Clinical 
stage, pathological grade and PBRM1 were all independent risk factors affecting the prognosis of patients with clear cell 
carcinoma of the kidney. Overall, the results suggest that PBRM1 is positively correlated with P53 in clear cell carcinoma of 
kidney (r=0.781, P=0.012). PBRM1 and P53 are both highly expressed in ccRCC and play an important role in the 
development of the disease. PBRM1 can also be used as an independent risk factor affecting the prognosis of ccRCC 
patients.  
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Clear cell renal cell carcinoma (ccRCC) is a 
pathological type of kidney cancer, accounting for 
about 85% of kidney cancer. With the extension of 
human life span and the continuous improvement of 
diagnostic methods, its incidence has been increasing 
year by year
1
. Globally, 0.431 million people are 
affected by kidney cancer, and approximately 0.179 
million people have succumbed to this disease in 
2020
2
. The early symptoms of clear cell carcinoma of 
the kidney are mainly systemic, such as fever and 
fatigue, which are not specific and easy to be ignored, 
and are more than found in physical examination
3,4
. 
Reports show that about 25% of the patients in the 
diagnosis for the first time there has been a tumor 
volume increase, to some extent, diffusion and 
transfer, more performance for blood in the urine and 
kidney area pain and other symptoms, it belongs to a 
type of malignant degree is low in the kidney, but it’s 
in clinical practice with more granular cell carcinoma, 
spindle cell carcinoma, lead to the microscope 
classification is more difficult
5,6
. Most clear cell 
carcinoma of the kidney is treated by radical 
nephrectomy, but the rate of tumor metastasis with 
blood transport is high. Once lymph node metastasis 
occurs, the survival time of most patients is less than 





Renal clear cell carcinoma development process is 
complex, often recognized as tumor for its genetic 
disorders or tumor-suppressor gene inactivation closely 
linked. However, the occurrence and development of its 
relevant molecular biology foundation has not been 
elucidated till now
8
.. Relevant studies have shown that 
PBRM1 is abnormally expressed in breast cancer and 
has the function of tumor inhibition. Other studies have 
shown that P53 gene mutation is related to the biological 
behaviour of renal cell carcinoma to a certain extent
9,10
. 








correlation between PBRM1 and P53 by detecting their 
expressions in clear cell carcinoma of the kidney. 
 
Materials and Methods 
A total of 70 cases of cancer tissues were removed 
by radical nephrectomy from December 2018 to 
January 2019 in our hospital were selected; and 24 
cases of normal renal tissue from healthy volunteers 
were collected. Inclusion criteria: (i) Age 6-18;  
(ii) clear cell carcinoma of the kidney was diagnosed 
by pathological examination and professional 
pathologist; (iii) all had complete clinicopathological 
data; (iv) all knew the content of this study and signed 
the informed consent; and (v) all met the approval 
requirements of the ethics committee of our hospital. 
Exclusion criteria: (i) patients with malignant tumor; 
and (ii) chemoradiotherapy. By age, 36 cases were 
aged 6 years and below, and 34 cases were aged over 
6 years. By sex, there were 30 males and 40 females. 
According to the tumor size, 35 cases were 5 cm or 
below, 35 cases were above 5c, and 25 cases were 
stage I~II and 45 cases were stage III~IV according to 
clinical stages. According to pathological classification, 
there were 46 cases of G1, 12 cases of G2 and 12 
cases of G3.  
 
Materials 
Rabbit anti-human PBRM1 and P53 were 
purchased from Shanghai Huangring Biotechnology 
Co., Ltd. Immunohistochemical kit was purchased 
from Changzhoubeiyuanxin Biotechnology Co., Ltd. 
Goat serum working fluid was purchased from 
Anhuijingke Biotechnology Co., Ltd. PBS powder 
was purchased from Beijing Kailiki Biotechnology 
Co., Ltd. Neutral gum was purchased from Shanghai 
Yihui Biotechnology Co., Ltd. Citric acid antigen 
repair buffer solution was purchased from Beijing 
Solebo Technology Co., Ltd. 
Paraffin slicing machine was purchased from 
Shenzhenruiwode Life Technology Co., Ltd. Table 
high speed cryogenic centrifuge purchased from 
Hangzhouaosheng Instrument Co., Ltd. Booth sheet 
baking machine was purchased from Hubeihuida 
Instrument co., Ltd. Anti-stripping machine was 
purchased from Shanghai Aladdin Biochemical 
Technology Co., Ltd. 
 
Immunohistochemical method and interpretation criteria 
Specimens of clear cell carcinoma of the kidney 
and normal kidney tissues were selected, placed in 
10% forfalin, embedded in paraffin, then placed in a 
slicer, and the thickness of sections was set to 5 μm. 
Immunohistochemical kit prepared in advance was 
taken and immunohistochemical staining was carried 
out according to its operating procedures.  PBRM1 is 
mainly expressed in the cytoplasm, cell membrane, 
P53 mainly in the nucleus. The proportion of positive 
cells was determined by cell sex status and the 
proportion of positive cells: no positive cells were 
found to score 0, the proportion of positive cells <1% 
to score 1, 1~10% to score 2, 10~50% to score 3, and 
more than 50% to score 4. Score 0, light yellow 1, 
brown 2, brown 3, negative expression ≤3, positive 
expression >3. The patients were followed up by 
telephone, and the survival and prognosis of the 
patients were analyzed. 
 
Statistical methods 
SPSS22.0 software package was used for statistical 
analysis. The expression of PBRM1 and P53 in the 
sample tissues was tested by χ
2
 test. The survival 
curve of patients with renal clear cell carcinoma was 
plotted by Kepaln-Meier method. COX proportional 
risk regression model was established to analyze the 
prognosis of patients with clear cell carcinoma of the 
kidney. Value of P <0.05 was considered significant. 
 
Results 
Expression of PBRM1 and P53 in clear cell carcinoma of 
kidney and normal kidney tissue 
The positive expression rate of PBRM1 in clear 
renal cell carcinoma tissues was 62.86%, significantly 
higher than that in normal renal tissues 8.33%  
(P <0.05). The positive expression rate of P53 in clear 
renal cell carcinoma tissues was 40% (28/70) whereas 
there was no expression in normal renal tissues  
(P <0.05) (Fig. 1). 
 
Correlation between PBRM1 and P53 and clinicopathological 
parameters of clear cell carcinoma of the kidney 
The expression level of PBRM1 was correlated 
with pathological grade and clinical stage of patients 
with clear cell carcinoma of the kidney (P <0.05), but 
not with age, sex and tumor size (P >0.05). P53 and 
expression levels were independent of age, sex, tumor 
size, pathological grade, and clinical stage of patients 
with clear cell carcinoma of the kidney (P >0.05) 
(Table 1). 
 
Correlation between PBRM1 and P53 and prognosis of clear 
cell carcinoma of kidney 
The 5-year survival rate of PBRM1-positive 
expression patients was 40.91% significantly lower 
than that of PBRM1-negative expression patients 
84.62%  (P <0.05).As shown in Fig. 2A.The 5-year 
survival rate of patients with positive expression  




of P53 was 50 % compared with 61.90% of  
patients with negative expression of P53 (P >0.05) 
(Fig. 2B). 
 
COX model analysis of patients with clear cell carcinoma of 
the kidney 
As revealed by Table 2, the clinical stage, 
pathological grade and PBRM1 were all independent 
risk factors affecting the prognosis of patients with 
clear cell carcinoma of the kidney. 
 
Correlation analysis between PBRM1 and P53 
PBRM1 was positively correlated with P53 in clear 
cell carcinoma of kidney (r=0.781, P=0.012). 
 
Discussion 
PBRM1 is a new type of gene. Clinical studies 
have shown that it has a high mutation rate and plays 
an inhibitory role in tumor onset and progression. 
However, in a special period, PBRM1 loses its 
activity due to damage, which eventually leads to the 
occurrence of tumors
11,12
. Relevant literature has 
shown that PBRM1 is an extremely critical member 
in the development of clear cell carcinoma of the 
kidney, and can play a role through cell apoptosis,  
Table 2 — COX model analysis of patients with  
clear cell carcinoma of the kidney 
Parameters SE Wald P 95% CI 
Gender 0.555 0.651 0.435 0.543~4.493 
Age 0.571 5.59 3.501 1.176~2.448 
Tumor size 0.611 11.937 0.082 2.462~5.803 
Clinical stage 0.572 8.331 0.005 1.691~15.168 
Pathological grade 1.672 9.551 0.003 1.846~15.117 
PBRM1exprssion 0.602 6.767 0.021 1.463~14.629 
P53 expression 0.609 3.093 0.090 0.896~9.217 
 
proliferation and other links
13
. However, the 
inactivation mechanism of PBRM1 and its tumor 
regulation mechanism are still not clear, and hence, it 
needs to be further explored for clear understanding 
of clinical prevention and treatment of clear cell 
carcinoma of kidney and the assessment of prognosis. 
Previous studies have shown that the expression of 
PBRM1 in renal cancer is significantly increased, and 
the positive expression rate is correlated with the 
degree of tumor differentiation and malignancy
14
. P53 
gene change is a common type in human solid tumors, 
and it plays a significant role in regulating cell cycle 
and cell differentiation. Currently, there are many 
studies on P53, and it has been reported that the 
 
 
Fig. 1 — Expression of PBRM1 and P53 in clear cell carcinoma and normal renal tissue. (A) positive expression of PBRM1 in clear cell 
carcinoma of kidney; (B) negative expression of PBRM1 in normal renal tissue; (C) positive expression of P53 in clear cell carcinoma of 
kidney; and (D) negative expression of P53 in normal renal tissue 
 




PBRM1 χ2 P P53 χ2 P 
NE (n=26) PE (n=44)   NE (n=42) PE (n=28)   
Age (year)    1.693 0.193   5.042 0.999 
≤18 36 16 20 - - 17 19 - - 
>6 34 10 24 - - 25 9 - - 
Gender    3.717 0.054   2.188 0.110 
Male 30 15 15 - - 15 15 - - 
Female  40 11 29 - - 27 13 - - 
Tumor size (cm)    2.143 0.143   0.952 1.000 
≤5 35 17 18 - - 19 16 - - 
>5 35 9 26 - - 23 12 - - 
Clinical stage    7.540 0.006   0.259 1.132 
I~II stage 25 16 9 - - 14 11 - - 
III~IV stage 45 10 35 - - 28 17 - - 
Pathological grade    12.984 0.002   0.686 0.710 
G1 46 24 22 - - 26 20 - - 
G2 12 1 11 - - 8 4 - - 
G3 12 1 11 - - 8 4 - - 
[NE:Negative expression; PE: Positive expression] 
 




positive expression rate of P53 gene in kidney tumor 
is 30~60% when it is changed
15
. There are different 
opinions about P53 in renal clear cell carcinoma, and 
some scholars believe that its expression level is 
related to the degree of tumor differentiation, invasion 
depth and lymphatic metastasis, and it can be  
used as an independent prognostic indicator
16
.  
Few others have reported that the expression level of 
P53 is independent of lymph node metastasis and its 
ratio can be used as an independent prognostic 
indicator. 
In this study, immunohistochemical approach was 
used to determine PBRM1 and P53 in clear cell 
carcinoma of kidney and normal kidney tissues. The 
results have shown that the positive expression rate of 
PBRM1 in clear cell carcinoma of kidney and normal 
kidney tissues was 62.86%, significantly higher than 
that of PBRM1 in normal kidney tissues (8.33%  
(P <0.05). The positive expression rate of P53 in clear 
renal cell carcinoma tissues was 40 % while there was 
no expression in normal renal tissues (P <0.05). These 
results suggest that PBRM1 and P53 play an 
important role in the pathogenesis and progression of 
clear cell carcinoma of the kidney, in which P53 plays 
a role as an anticancer gene. PBRM1 expression level 
was correlated with pathological grade and clinical 
stage of patients with clear cell carcinoma of the 
kidney (P <0.05). It suggested that the increased 
PBRM1 positive expression rate may be closely 
associated with clear cell carcinoma of the kidney, 
which is of important reference value for the 
prediction of disease progression and disease severity. 
The 5-year survival rate of patients with PBRM1 
positive expression was 40.91% significantly lower 
than that of patients with PBRM1 negative expression 
(84.62% (P <0.05). Similarly, the 5-year survival rate 
of patients with positive expression of P53 was 50% 
compared with 61.90% of patients with negative 
expression of P53 (P >0.05). The results suggest that 
both PBRM1 and P53 can be used as effective 
indicators to evaluate the survival of patients. Clinical 
stage, pathological grade and PBRM1 were all 
independent risk factors affecting the prognosis of 
patients with clear cell carcinoma of the 
kidney.PBRM1 was positively correlated with P53 in 
clear cell carcinoma of kidney (r=0.781, P=0.012). 
 
Conclusion 
PBRM1 and P53 are both highly expressed in clear 
cell carcinoma of the kidney and play an important role 
in the occurrence and development of the disease. At the 
same time, PBRM1 can also be used as an independent 
risk factor affecting the prognosis of patients with clear 
cell carcinoma of the kidney. It is expected to be an 
important indicator for evaluating the progress and 
prognosis of patients with clear cell carcinoma of the 
kidney and a target for antitumor therapy. 
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